Moreover, overexpression of CD276 in tumor tissues frequently correlates with diminished tumor-infiltrating lymphocytes, hastened cancer progression, and adverse clinical outcome5, which makes it an attractive and promising target for cancer immunotherapy. The gene discussed is CD276; the disease is neoplasm.